Curve has developed a drug discovery platform to address the most challenging and complex disease targets. The company’s innovative technology allows high-throughput functional screening of a proprietary DNA-encoded (Microcycle®) library inside mammalian cells.

Curve is using this platform to develop a pipeline of first-in-class small-molecule therapeutics against challenging cancer targets, including intracellular protein-protein interactions and pioneer factors.